Conditions & Recovery · ScienceDaily — Cancer · June 4, 2026

Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival

For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic tumors—something many scientists once thought couldn't be done. In a major clinical trial, the treatment nearly doubled survival for patients with advanced disease and reduced the risk of death by 60%.

Originally published by ScienceDaily — Cancer. We curate and add context; they did the reporting.

Related learning